Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered by Benjamin B. Gelman
CENTRAL NERVOUS SYSTEM AND COGNITION (SS SPUDICH, SECTION EDITOR)
Neuropathology of HAND With Suppressive Antiretroviral
Therapy: Encephalitis and Neurodegeneration Reconsidered
Benjamin B. Gelman1
Published online: 10 April 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract HIV-1 infiltrates the central nervous system (CNS)
during the initial infection and thereafter plays a persistent role
in producing CNS dysfunction as the disease progresses. HIV-
associated neurocognitive disorders (HAND) are highly prev-
alent in HIV-infected patient populations, including currently
infected patients with good access to suppressive antiretroviral
therapy (cART). cART decreased the severity of CNS dys-
function dramatically and, in doing so, upended the neuro-
pathological foundation of HAND pathophysiology. It is clear
that the working concept of pathophysiology prior to cART,
which was driven by inflammation, encephalitis, and neuro-
degeneration, needs to be replaced. The NeuroAIDS field is
reluctant to take that important step. This review explores the
fact that the neuropathological concept that drove the field
before the era of cART no longer seems to fit with what is
commonly observed in patients treated successfully with
cART. The field clings to the pre-cART idea that HAND is
sequentially driven by virus replication in CNS, brain inflam-
mation (encephalitis), and neurodegeneration. Neurovirological,
clinicopathological, and gene expression correlations in cART-
treated patients, however, provide little strong support for it.
Introducing cART into clinical practice decreased HIVE,
inflammation, and degeneration but did not cure HAND. Brain
gene array data suggest that the neurovascular unit is a critical
target in virally suppressed patients with HAND. The
NeuroAIDS field needs an infusion of new ideas to steer
research toward issues of the highest relevance to virally
suppressed patients. With no suitable replacement imme-
diately within reach, devaluating formative ideas is under-
standably difficult to accept. The cliniconeuropathological
correlation in virally suppressed patients needs to be better
defined.
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Introduction
Central nervous system (CNS) infection is established early in
the course of HIV/AIDS. CNS pathology was a highly prev-
alent feature in the natural history of patients who were not
virally suppressed. The topic of HIV infection of the CNS has
enjoyed a sustained period of scientific and clinical interest for
over 30 years. The neuropathology of end-stage AIDS has
been illustrated comprehensively and is well-described in
many excellent book chapters and review articles [1, 2]. Im-
ages of the histopathology can be easily acquired in cyber-
space in these times and there seems little need to illustrate
them yet again. Updating a fast-moving field is potentially
useful nevertheless to discuss the existing body of knowledge
with a changed perspective. Current times have not been pro-
pitious for the discovery of exciting new developments in the
neuropathology of HIV/AIDS. The paucity of recent articles
with high impact makes an update of neuropathology
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challenging, but also heightens opportunities for analysis, re-
flection, and commentary. The need for new and genuinely
novel ideas in this field has never been greater. HIV-infected
patients and the new corps of enterprising young practitioners
both deserve to inherit a scientific legacy that points in a clear
direction that focuses on relevant problems. Accordingly, this
article provides commentary with the aim of spurring new
investigators to propel the field creatively forward.
There is a virtual haze of comorbid changes and/or age-
related pathologies that can occur in HIV-infected subjects.
When one wipes away the haze in patients who are compliant
with taking suppressive antiretroviral therapy (cART), the
overwhelmingly dominant HAND-associated neuropathology
observed at autopsy is Bno specific neuropathology.^ The lack
of a specific neuropathological change,which became themost
common outcome at autopsy at the close of the twentieth cen-
tury, has led to a dearth of novel breakthroughs in the neuro-
pathological literature for at least 15 years. The medical litera-
ture favors positive data and shuns negativity. Composing a
scholarly treatise regarding the disappearance of pathologies
that were prevalent formerly is perhaps more challenging than
describing the panoply of CNS changes observed before the
era of cART. Present circumstances in the era of cART have
benefited our patients substantially, but we still have not can-
onized a new cliniconeuropathological correlation for HIV-
associated neurocognitive disorders (HAND). With no clear-
cut replacement for the Bold^ neuropathology to guide us in the
era of cART, one can reasonably wonder what the actual mech-
anism of HAND really is. Therapeutic strategies of current
interest are based primarily upon neuropathologies that do
not occur with high prevalence. Given the low prevalence of
those pathologies in virally suppressed patients, their clinical
relevancy to HAND, which has an estimated prevalence of up
to 50 % [3], becomes increasingly dubious.
From a historical perspective, the most important
cliniconeuropathological concept in the field was established
prior to the era of cART in patients in whom virus replication
was not suppressed medically. In those patients, progression
to end-stage AIDS was virtually certain to occur and about
20 % of patients had HIV encephalitis (HIVE) at autopsy [4,
5]. This neuropathological lesion in the brain was first labeled
a Bsubacute^ type of inflammatory process characterized by
several features in combination, the most important of which
was evidence of HIV replication in mononuclear phagocytes
(macrophages and microglial cells).
Microglial Nodules
Foremost among the histological changes in HIVE was the
presence of microglial nodules (MGN), which are activated
microglial cells arranged in clusters of variable sizes.
Microglial cells are the resident histiocytes of the CNS and,
combined with brain macrophages, are the major reservoir of
replicating HIV in the brain. Unlike macrophages which orig-
inate in bone marrow, microglial cells arrive early in develop-
ment from the yolk sac and can reproduce locally in the CNS
[6]. MGNs can occur in either gray or white matter almost
anywhere in the CNS. They can be striking in their abundance
in the tissue but are not diagnostic for HIVE because they may
be observed in several other kinds of brain infection.When the
MGNs are immunostained for HIV proteins such as gp41,
HIVp24, or gp120 they are considered to be specific to HIV
infection of these cells. Over the years, some confusion was
produced because case material often contained an abundance
of MGNs without other lesions associated with HIVE (to be
discussed). These cases still may be diagnosed Bmicroglial
nodule encephalitis^ (MGNE) in lieu of HIVE because other
infectious agents could not be readily ruled out. It was a crit-
ical diagnostic dilemma prior the cART era because encepha-
litis caused by opportunistic pathogens such as cytomegalovi-
rus and Toxoplasma ghondii also produced MGNs in immu-
nosuppressed patients with AIDS [1, 2, 7••]. The
neurovirological underpinnings of HIVE and MGNE diagno-
ses were recently unraveled. It was shown that HAND with
HIVE and HAND with MGNE both are associated with high
rates of HIV replication (HIV RNA) in the brain. As expected,
brain HIV replication is much higher in HIVE than MGNE,
which suggests that there is a neuropathological progression
of the disease from lower to higher replication rates. In pa-
tients with HAND without either of the two diagnoses, brain
HIV RNA and DNA were not significantly higher than pa-
tients without HAND. Interestingly, HANDwithout these two
pathologies was significantly correlated with HIV replication
in blood plasma, but not in the brain or CSF. Apparently,
systemic viral suppression is just as or more critical than viral
suppression within the CNS in these patients [7••].
Multinucleated Giant Cells and Macrophages
in HIVE
The Bhallmark^ lesion of HIVE is the multinucleated giant
cell (MNGC) [5]. These cells represent mononuclear phago-
cytes productively infected with HIV that have undergone
cellular fusion mediated by the HIV fusion protein gp41.
MNGCs are most often observed around blood vessels and
resemble other kinds ofmacrophage giant cells in their general
appearance such as those seen in granulomatous inflamma-
tion. They are readily distinguishable from other kinds of
macrophage giant cells by their positive immunostaining with
antibody against HIV proteins, the lack of associated granu-
lomatous inflammation, and the clinical and pathological con-
text in which they are observed. This feature alone is generally
adequate tomake the diagnosis of HIVE in an infected patient;
other features of HIVE described herein are almost always
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present as well. Many single macrophages and/or clusters of
macrophages are usually present in HIVE. They are most
often seen around the blood vessels in white matter and often
contain hemosiderin pigment. Macrophages productively in-
fectedwith HIV-1 in the brain generally have anM2 (Brepair^)
phenotype; they are CD163+, CD14+/CD16+, and they con-
tain stainable HIV-1 antigens [8, 9].
Other Inflammatory Cell Changes in HIVE
Ancillary and often nonspecific neuropathological changes
beyond the key features mentioned above can contribute to a
wide spectrum of changes in HIVE. In isolation, these chang-
es are seldom specific enough to diagnose HIVE, but when
observed in combination with other features they contribute to
a highly characteristic constellation of changes. Diffuse
microglial cell activation (Bdiffuse microgliosis^) is common-
ly observed in HIV-infected brain tissue. It refers to an in-
crease in the number of cells with a dark-stained rod-shaped
nucleus scattered in the brain tissue. An increase in the density
of Brod cells,^ which are the elongated hematoxylin-stained
nuclei, can occur with or without the formation of MGNs.
They are usually present in HIVE and MGNE, but frequently
they are observed without either of the two diagnoses. The
expansion and heightened ramification of the cytoplasmic
processes of the activated microglial cells are not visible in
routinely stained tissue sections but are recognized with im-
munostaining for HLA-D, Iba-1, ferritin, and other antigens
[10, 11]. Other inflammatory cells that can be observed in
HIVE include scattered perineuronal lymphocytes. CNS T
lymphocytes are not required to make the diagnosis of HIVE
and they lack specificity when observed. Indeed, their pres-
ence in high abundance serves to heighten suspicion that an-
other agent that can cause encephalitis might be present. Even
though lymphocytic infiltration is seldom the most telling or
prominent, brain lymphocyte subsets conduct regular immune
surveillance in the CNS and still could play a seminal role in
the pathophysiology of HIVE such as with neuronal killing
[12]. Infiltration of the brain with acute inflammatory cells
such as neutrophils and eosinophils in HIVE is not likely to
be important because they do not host HIV infection. The
basic nature of the inflammatory reaction to HIV infection in
the CNS is generally considered to be Bsubacute^ given the
lack of neutrophils.
Astrocyte Changes in HIVE
In HIVE astrocyte hypertrophy and glial scarring are observed
best in brain white matter. The hypertrophy is a nonspecific
reaction that occurs in all types of brain injury. HIV-infected
astrocytes are not morphologically different in a routine
neuropathological examination. Diagnostically, their chief
value is in establishing that damage has occurred in the setting
of inflamed brain tissue. The role of astrocytes remains of
great interest because in vivo and in vitro data indicate that
astrocytes can be infected with HIV [13]. They also can par-
ticipate in antigen presentation [14]. HIV-infected astrocytes
do not produce assembled viruses very effectively and are not
likely to be the main contributor to CNS HIV replication rates.
Astrocyte infection is very important because of its potential
ability to support viral latency in the brain. In cART-treated
and naïve patients both, reverse transcribed HIV DNA is in-
tegrated into the host cell genome and becomes Blatent^ in a
highly limited number of host cells. Virally latency is defined
as HIV DNA integrated into the host cell genome that is tran-
scriptionally silenced and immunologically inert, yet capable
of transcriptional reactivation to produce assembled viruses
that are fit to infect other host cells. Upon stopping cART, it
is the latent pool of HIV DNA that Breseeds^ active HIV
replication and prevents the complete eradication of HIV in-
fection. Data thus far indicate that integrated HIV DNA is
present in a substantial number of astrocytes in patients with
HIVE [15••]; it remains unclear whether the astrocyte pool of
HIV DNA contributes to the pool of latent HIV that reseeds
the CNS with replicating HIV when cART is stopped. If so,
the astrocyte reservoir of latent HIV is a highly significant
pool of virus that would need to be dealt with in therapies to
eradicate the virus from the CNS.
Neuronal Changes and BNeurodegeneration^
in HIVE
In the era of cART, the literature on neuronal death and drop-
out in HIV-infected people remains highly difficult to judge in
terms of its clinical relevancy. The difficulties are quite com-
plex and have been discussed [1]. The essence is that with
HIVE, inflammation damages neuronal viability and leads
some of the cells to drop out. In patients with HIVE, it can
be logically argued that neuronal dropout is contributory to
HAND, and that HIV-associated dementia is a type of neuro-
degenerative disease. Pursuing a Bneuroprotective^ strategy in
model systems that mimic HIVE is of clinical relevance in
patients with HIVE. The field continues to hold that, when
HIVE is not present, inflammation drives HAND and fuels
neurodegeneration. But the same underlying neuropathology
in virally suppressed patients without HIVE has never been
clearly substantiated [16]. That in turn begs the question of
why protecting against neurodegeneration (in parallel with
reducing inflammation and viral replication) remains a main-
stay in the search for pharmacotherapies for HAND.
If one broadens the definition of neurodegeneration to in-
clude nonlethal and/or reversible changes in neuronal func-
tion, then neuroprotection of virally suppressed individuals
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remains a logical therapeutic approach. Evidence which sup-
ports this concept includes brain images showing functional
adaptation occurring in HIV-infected patients who do not have
neurocognitive impairment [17, 18, 19•]. Neurochemical data
from autopsy specimens also reveal that nonlethal synaptic
accommodation of neurotransmitter systems is related to
HAND, including heightened neocortical dopaminergic tone
[20•]. Adopting a broader functional definition of neurode-
generation is, however, at odds with the traditional definition
of neurodegenerative diseases such as Alzheimer’s or
Parkinson’s diseases. Those diseases are defined classically
as being due to an irreversible neuronal death, cell dropout,
and clear-cut morphological destruction of neuronal elements;
their clinical manifestations only occur after a very large pro-
portion of the neuronal elements have been destroyed. Those
kinds of neuropathological changes have not been observed in
recent times with consistency in patients with HAND, where-
as nonlethal changes in neuronal function probably do occur
[20•, 21••]. These milder types of changes are likely to under-
lie the milder neurocognitive impairments that are observed.
Abnormal neuronal function (versus death and dropout) is
akin to the metabolic types of encephalopathies, which are
traditionally described in a completely different chapter of
our neuropathology textbooks. Thus, neuroprotection from
metabolic types of damage in patients with viral suppression
seems an apt description of what is probably happening (ver-
sus neuronal death and dropout).
With survival to older ages in virally suppressed patients,
roles of biological and pathological brain aging (such as
Alzheimer’s or Parkinson’s diseases) have been suggested to
be potentially interactive with HAND at the histomorphological
level. The underlying hypothesis is that the intersection of age-
associated and HIV-associated neurodegeneration could mutu-
ally exacerbate each other. The neuropathological literature on
this is fragmented, controversial, and inconclusive [22•]. As
noted, the case for neuronal death, dropout, and classical neu-
rodegeneration in virally suppressed patients with HAND is
increasingly difficult to substantiate. That makes potential syn-
ergy with age-related neurodegenerative diseases at the mech-
anistic level difficult to accept. It is true that neuropathological
elements of classical neurodegenerative diseases have begun to
appear in older people with HIV infection. And surveys show
that elderly people with HIV infection are more vulnerable to
neurocognitive impairment. But such changes also begin to
occur in aging populations that are not HIV infected. One can
just as logically hypothesize that age- and HIV-associated ef-
fects could run in parallel with no mechanistic overlapping, and
contribute additively to neurocognitive declines in more elderly
HIV-infected people. The postulated evolution of a
neuropathologically distinct subtype of HAND in people who
have age-associated neuropathologies remains to be convinc-
ingly validated. It remains unlikely to be disproved completely
in the near future, in part because proving a negative
proposition is difficult to do and also because negative data
can be seen as unwelcome news.
White Matter Changes in HIVE
White matter damage adds to the spectrum of changes in
HIVE. The white matter changes can vary in type, intensity,
and their distribution in the brain. White matter edema leads to
loss of staining of themyelin (Bpallor^). Outright acute destruc-
tion of myelin due to exuberant HIV-1 replication and inflam-
mation can occur rarely in HIVE, but more typically slow
myelin loss and its phagocytosis by macrophages are restricted
to perivascular sectors [23, 24]. Brain imaging studies suggest
that focal white matter anomalies are relatively common in
HIV-infected patients, including many virally suppressed
patients who do not have HIVE, but the neuropsychological
implications of that still have not been elucidated clearly [25].
The Neurovascular Unit and Its Potential
Importance in the Cliniconeuropathological
Correlation
Gaps in our understanding of the cliniconeuropathological
correlation of HAND persist. Each of the neuropathological
features reviewed above in the context of their clinical rele-
vancy (or lack of) has been discussed recently [1]. Recent
experience has shown convincingly that the overwhelming
majority of patients today who are virally suppressed do not
have HIVE or MGNE. As well, most of these patients do not
have substantial HIV replication in brain tissue [7••] and they
do not have an inflammatory gene expression profile in brain
tissue [21••]. Of all the CNS structures that are abnormal in
virally suppressed patients with HAND, the neurovascular
unit (NVU) may be the most important regarding the
cliniconeuropathological correlation. The NVU refers to the
blood vessel compartment in the CNS and its interface with a
web of physical and functional interactions with brain paren-
chyma [26–28]. The interconnected parts include astrocyte
foot processes, neuronal processes and synapses, endothelial
cells, pericytes, perivascular macrophages and microglial
cells, CNS extracellular spaces, the subarachnoid spaces and
cerebrospinal fluid, and perhaps most importantly, blood plas-
ma. Subtle changes in blood plasma are prevalent in HIV-
infected patients [29–31], and systemic changes as reflected
in the vascular compartment are indeed significantly correlat-
ed with HAND. The anemia of chronic inflammation (low red
cell volume), and increased plasma lipopolysaccharide due
translocation of gut bacteria are both significantly correlated
with HAND [32•, 33]. As noted above, the neurovirological
correlation in virally suppressed patients with HAND may be
weaker than the correlation with plasma viral replication [7••].
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The NVU is, therefore, situated anatomically at the critical
junction between CNS parenchyma and the plasma compart-
ment at the luminal surface of vascular endothelial cells. Its
best-known function is maintaining a highly selective physical
barrier between blood plasma and brain parenchyma known as
the blood-brain barrier (BBB). In HIVE, the BBB is leaky and
leads to cerebral edema by permitting blood plasma to enter the
CNS. Experimental systems suggest that this could be detri-
mental to brain function. Cerebral edema and opening of the
BBB is, however, a nonspecific response to CNS injury. It is
not clear whether it reflects an epiphenomenon of brain inflam-
mation versus a substantial cause of brain dysfunction in HIVE.
As well, we do not know whether it occurs substantially in
HAND patients taking cARTwho do not have HIVE, enceph-
alitis, or other ongoing neuropathological process. Because the
BBB is damaged in HIVE, which in turn is correlated with
HAND, it is not surprising that the BBB disturbance was cor-
related with HAND in studies before the era of cART [23].
Beyond acting as a physical barrier, other functions of the
NVU could be perturbed in cART-treated patients who are
virally suppressed. As noted, endothelial cell surfaces in con-
tact with blood plasma transmit signals to neurons and glia via
the NVU (without apparent breakdown in the BBB). These
processes may still be perturbed in virally suppressed patients
who have low level inflammatory changes in blood plasma
[28–31, 32•, 33–35]. Another key role of the NVU is the
regulation of microvascular blood flow. The inhibitory neuro-
transmitter gamma aminobutyric acid (GABA) controls
changes in regional microvascular blood flow via the NVU
through influences on contractility of pericytes around capil-
laries and arteriolar smooth muscle [26–28]. Studies using
blood oxygenation level-dependent (BOLD) functional mag-
netic resonance imaging (fMRI) show convincingly that blood
flow in specific brain regions is perturbed in cART-treated
patients, with and without HAND [19•]. GABAergic trans-
mission is well-known to be abnormally low in HIV-infected
brain tissue [21••]. Thus, abnormal GABAergic neural trans-
mission might be involved with the changes in microvascular
blood flow in virally suppressed patients.
Compelling evidence that the NVU is probably important
in HAND without HIVE was obtained from a recently report-
ed brain gene expression profile [21••]. The study examined
over 56,000 gene transcripts in neuropsychologically impaired
people with HIVE who lacked CNS viral suppression, and also
in people who were virally suppressed in the blood and brain
and did not have HIVE. Three different sectors of the brain
were examined. Over 1000 brain transcripts were regulated in
HANDwith HIVE. In sharp contrast, brain gene regulation was
highly restricted in virally suppressed patients with HAND
without HIVE. These individuals had abnormal transcription
regulation limited to a network of brain genes expressed by
endothelial cells. Many of these endothelial-type molecules
are shed; their concentrations are increased in blood plasma
and are not completely restored to normal in virally suppressed
patients [35]. The implication overall is that perturbation of
neurovascular biology may be a keystone process in patients
who are virally suppressed, whereas in the patients without
viral suppression, brain inflammation is a more prevalent force.
Heightened awareness that there are two types of HAND with
divergent neurovirological [7••] and brain transcriptional [21••]
patterns was suggested two decades ago before the introduction
of effective viral suppression [36].
Neuropathology and Eradicating Latent HIV
in the CNS
In 2015, the HIV/AIDS research enterprise worldwide is en-
gaged in an effort to cure AIDS. The effort is focused on
eradicating from the body a small pool of genomically inte-
grated but transcriptionally silent cellular HIV DNA. This
Blatent^ pool of HIV DNA is apparently not diminished using
current cART formulations; when cART is stopped, the latent
HIV pool Breseeds^ the pool of replicating virus in the body
[37]. The nature of the latent pool of HIV DNA in the CNS
has not been characterized as yet, and some have questioned
whether its eradication from the body is scientifically feasible.
From neurovirological data obtained at autopsy, it is well doc-
umented that genomic HIV DNA is present in many brain
specimens. In many patients, there is substantial divergence
between the size of the HIV DNA pool and the replicating
pool (HIVRNA) [7••]. It is evident that the CNS compartment
can be variously enriched with, or depleted of, HIV DNA
relative to the viral replication rate. Since cells that host latent
HIVare likely to be immunologically Binert^ and invulnerable
to immune surveillance [37], there is very little reason to be-
lieve that pathological inflammation such as that observed in
HIVE would be linked to it. Similarly, Bneurodegeneration^
driven by CNS inflammation would be unlikely to be associ-
ated with the CNS pool of latent HIV DNA. A recent report
suggested that a transcriptionally silenced HIV DNA pool in
10 infected brain specimens was related to high expression of
the microglial cell transcription factor BCL11b [38]. It awaits
independent replication in more patients, yet intriguingly sug-
gests that repressing the pool of latent HIV DNA in microglial
cells is potentially feasible.
Whether HAND is associated with enrichment of the CNS
pool of latent HIV DNA (relative to the CNS replication rate)
is not clear. Current thinking on this topic is speculative at
best. Available data on HIV RNA and total HIV DNA from
autopsy brain specimens show that a very low viral replication
rate (and low total HIV DNA concentration) in the CNS, as
seen in virally suppressed patients, is not substantially correlat-
ed with HAND. In contrast, very high rates of viral replication
in the CNS (with high concentrations of HIV DNA), as seen in
HIVE patients not taking cART, are correlated significantly
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withHAND [7••]. Inclusion of the latter type of patients in most
surveys is what drives the significance of this correlation over-
all. In a follow-up to that study, the authors measured integrated
HIV DNA (a more specific measure of viral latency in tissue)
using the two-step Alu-gag assay in 29 of the brain specimens.
The neurovirological correlation using integrated HIV DNA
(both the coefficient and the regression line) was not different
from results using total HIV DNA or HIV RNA. The result
favors the hypothesis that the latent pool of HIV in the brain
per se is no more influential to the cliniconeurovirological cor-
relation than are the other two viral pools that were measured
(the author’s unpublished observation).
Conclusions: the Future
The neuropathology of HIV infection changed drastically when
cART was introduced into clinical practice. The neuroAIDS
field clings to most tenets of the Bold^ pathology of
unsuppressed patients, especially the concepts that encephalitis,
neurodegeneration, and CNSHIVreplication are the key drivers
of HAND. Once considered seminal to the field, those tenets are
of increasingly lower relevance clinically. The lack of specific
pathoanatomical changes in virally suppressed patients means
that the cliniconeuropathological correlation of HAND is driven
by subtler and potentially reversible neurometabolic changes,
such as those associated with synaptic transmission and neural
plasticity [20•]. Correlation between HAND and systemic pa-
thologies also implies a possible metabolic encephalopathy that
is one component of a systemically driven illness. Establishing a
new conceptual framework is painful and risks Bthrowing the
baby out with the bath water.^ But the NeuroAIDS field is ripe
for a change. The next generation of practitioners and scientists
faces a very stiff headwind to meet that challenge.
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